NCT01718613View on ClinicalTrials.gov

Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

May 31, 2018

Conditions
Septic Shock
Interventions
DRUG

Vasopressin

Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement

DRUG

Norepinephrine

Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement

Trial Locations (1)

01246000

Instituto do Cancer do Estado de Sao Paulo, São Paulo

All Listed Sponsors
lead

Instituto do Cancer do Estado de São Paulo

OTHER

NCT01718613 - Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients | Biotech Hunter | Biotech Hunter